Jonathan Buggey, MD
Cardiovascular Disease · Akron, OHNPI 1013250133
Payments from drug & device makers
Across 84 payments — averaging $50.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- United Therapeutics Corporation$342
- AstraZeneca$163
- Novartis$156
- Amgen$153
- Gilead$144
- plus $471 from 16 others
What the payments were for
- Consulting fees$1303%
- Travel & lodging$1,00324%
- Food & beverage$2,89968%
- Education$2175%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 32 | $2,820 |
| United Therapeutics Corporation | 5 | $342 |
| AstraZeneca | 11 | $163 |
| Novartis | 3 | $156 |
| Amgen | 4 | $153 |
| Gilead | 1 | $144 |
| Johnson & Johnson | 5 | $62 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $48 |
| Portola Pharmaceuticals, LLC | 1 | $41 |
| Pfizer | 3 | $40 |
| Merck | 1 | $31 |
| E.r. Squibb & Sons, L.L.C. | 2 | $30 |
| Esperion Therapeutics, Inc. | 1 | $29 |
| Medtronic | 2 | $28 |
| Actelion Pharmaceuticals US, Inc. | 1 | $25 |
| Lantheus Medical Imaging, Inc. | 1 | $23 |
| Sanofi | 1 | $21 |
| Bayer | 1 | $21 |
| Vifor Pharma, Inc. | 1 | $20 |
| Cvrx, Inc. | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,249 in reported general payments places this provider in the 65th percentile of 827 cardiovascular disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 60 | $1,593,120 |
| EntrestoSacubitril/Valsartan | 351 | $574,027 |
| EliquisApixaban | 437 | $520,323 |
| AdempasRiociguat | 34 | $455,187 |
| Tyvaso DpiTreprostinil | 15 | $351,591 |
| FarxigaDapagliflozin Propanediol | 246 | $278,199 |
| UptraviSelexipag | 11 | $253,331 |
| OpsumitMacitentan | 16 | $193,042 |
| JardianceEmpagliflozin | 140 | $187,485 |
| Ambrisentan | 54 | $120,704 |
| XareltoRivaroxaban | 28 | $42,959 |
| Repatha SureclickEvolocumab | 30 | $34,050 |
| CorlanorIvabradine Hcl | 11 | $13,247 |
| BrilintaTicagrelor | 14 | $13,241 |
| Sildenafil Citrate | 52 | $10,124 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $40 | $2,113,443497 claims |
| NovartisEntresto | $156 | $574,027351 claims |
| BayerAdempas | $21 | $455,18734 claims |
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $25 | $446,37327 claims |
| AstraZenecaFarxiga, Brilinta | $163 | $291,441260 claims |
| Johnson & JohnsonXarelto | $62 | $42,95928 claims |
| AmgenCorlanor | $153 | $13,24711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 827 cardiovascular disease providers in Ohio.
Other cardiovascular disease in Akron
- Joseph PietrolungoAkron$197K
- Joseph RedleAkron$167K
- Samir KapadiaCleveland$11.1M
- Steven NissenCleveland$5.3M
- Milind DesaiCleveland$5M
- Abraham LincoffCleveland$3.6M
- Carlos HubbardCleveland$3.1M
- Guilherme AttizzaniCleveland$2.8M
- Wai Hong TangCleveland$2.2M
- Bhola RamaMarion$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.